Tower Research Capital LLC TRC Has $51,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Tower Research Capital LLC TRC lowered its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 74.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,331 shares of the company’s stock after selling 6,821 shares during the period. Tower Research Capital LLC TRC’s holdings in Viridian Therapeutics were worth $51,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of VRDN. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Viridian Therapeutics by 122.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock valued at $182,000 after purchasing an additional 4,610 shares during the period. Arizona State Retirement System bought a new stake in Viridian Therapeutics in the 4th quarter valued at about $208,000. Raymond James & Associates boosted its holdings in Viridian Therapeutics by 71.1% in the 3rd quarter. Raymond James & Associates now owns 15,164 shares of the company’s stock valued at $233,000 after purchasing an additional 6,303 shares during the period. Dark Forest Capital Management LP bought a new stake in Viridian Therapeutics in the 3rd quarter valued at about $264,000. Finally, New York State Common Retirement Fund boosted its holdings in Viridian Therapeutics by 9.7% in the 4th quarter. New York State Common Retirement Fund now owns 17,495 shares of the company’s stock valued at $378,000 after purchasing an additional 1,545 shares during the period.

Viridian Therapeutics Price Performance

NASDAQ:VRDN traded down $0.34 on Tuesday, hitting $13.26. The company had a trading volume of 898,244 shares, compared to its average volume of 926,235. The stock has a market capitalization of $832.33 million, a price-to-earnings ratio of -2.49 and a beta of 1.07. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $16.96 and a two-hundred day moving average of $17.55. Viridian Therapeutics, Inc. has a 52 week low of $10.93 and a 52 week high of $28.99.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.37). The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. Viridian Therapeutics’s revenue for the quarter was down 31.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.13) EPS. On average, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.39 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on VRDN. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Viridian Therapeutics in a report on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Viridian Therapeutics in a report on Wednesday, March 20th. Wedbush upped their price target on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Finally, B. Riley cut their price target on shares of Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 21st. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $36.60.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.